BRCA1 and ovarian carcinoma: Olaparib (Lynparza; AstraZeneca) is the most extensively studied PARP inhibitor in patients with advanced BRCA1/2 mutated ovarian cancer and has now received Food and Drug administration (FDA) and European Medicines Agency (EMA) regulatory approval in the relapsed and maintenance treatment settings, respectively.